person · Reporting owner

Jovan-Embiricos Morana

Disclosed activity across 3 companies

Tapewire entity: 41364
SEC CIK: 0001575745

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kalaris Therapeutics, Inc.KLRS · Entity 6805	Director	June 03, 2026	June 04, 2026
TCR2 THERAPEUTICS INC.TCRR · Entity 94327	10% owner	December 18, 2019	December 20, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date June 03, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02	Direct	9,000	Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

TCR2 THERAPEUTICS INC.

Report date December 18, 2019 · Filed December 20, 2019

Jointly reported with Globeways Holdings Ltd, Globeways Holdings II Ltd, F2 Capital I 2015 Ltd, F2 Captial I 2017 Ltd, F2 MG Ltd, F2 Bioscience II 2017 Ltd, F2 - TPO Investments LLC, F2 BBG LLC, F2 Capital I 2019, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Fund	89,217	Reported balance After 2019-12-18 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2019-12-18 · Sale · Disposed 458 · Balance 89,217 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	191,309	Reported balance After 2019-12-18 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2019-12-18 · Sale · Disposed 2,433 · Balance 191,309 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	82,575	Reported balance After 2019-12-19 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2019-12-19 · Sale · Disposed 6,642 · Balance 82,575 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	155,986	Reported balance After 2019-12-19 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2019-12-19 · Sale · Disposed 35,323 · Balance 155,986 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	713,723	Reported balance After 2019-12-20 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2019-12-20 · Other · Disposed 586,153 · Balance 713,723 F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners. F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	161,024	Reported balance After 2019-12-20 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2019-12-20 · Other · Disposed 13,847 · Balance 161,024 F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners. F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	361,665	Reported balance Holding disclosure · report date 2019-12-18 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 361,665 F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	432,319	Reported balance Holding disclosure · report date 2019-12-18 · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · Balance 432,319 F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Fund	330,238	Reported balance Holding disclosure · report date 2019-12-18 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 330,238 F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.

F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.

F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cullinan Therapeutics, Inc.

Report date August 02, 2022 · Filed August 05, 2022

Jointly reported with F2 Vision SCS

Section 16 reporting ended · disclosed 2022-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,255,963	Last balance in matching sequence After 2022-08-04 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2022-08-02 · Sale · Disposed 4,792 · Balance 1,301,081 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Row 2 · 2022-08-03 · Sale · Disposed 19,129 · Balance 1,281,952 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Row 3 · 2022-08-04 · Sale · Disposed 25,989 · Balance 1,255,963 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Globeways Holdings Ltd.	1,136,525	Reported balance Holding disclosure · report date 2022-08-02 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 1,136,525 F5: These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 Bioscience I 2017 Ltd.	537,392	Reported balance Holding disclosure · report date 2022-08-02 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 537,392 F6: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 MG Ltd.	325,333	Reported balance Holding disclosure · report date 2022-08-02 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 325,333 F7: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2-TPO Investments, LLC	622,175	Reported balance Holding disclosure · report date 2022-08-02 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 622,175 F8: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 Bio TD, LLC	71,599	Reported balance Holding disclosure · report date 2022-08-02 · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · Balance 71,599 F9: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 MC, LLC	214,798	Reported balance Holding disclosure · report date 2022-08-02 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 214,798 F10: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy F2 GC, LLC	104,762	Reported balance Holding disclosure · report date 2022-08-02 · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · Balance 104,762 F11: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Morana Jovan-Embiricos	207,803	Reported balance Holding disclosure · report date 2022-08-02 · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · Balance 207,803 F12: These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F6: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F7: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F8: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F9: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F10: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F11: These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F12: These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 03, 2026 Filed Jun 4, 2026 20:38 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $4.72	$0.00	Disclosure SEC source: 0001193125-26-257564 · ownership.xml · derivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document
April 10, 2025 Filed Apr 11, 2025 21:08 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0000950170-25-053372 · ownership.xml · derivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service. Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:05 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0000950170-24-070602 · ownership.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,197 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
May 11, 2023 Filed May 12, 2023 21:00 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029095 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,197 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
August 04, 2022 Filed Aug 5, 2022 01:01 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	25,989	$14.31	$371,788.24	Disclosure SEC source: 0001104659-22-086343 · tm2222660-1_4seq1.xml · nonDerivative · entry 3 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,255,963 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 03, 2022 Filed Aug 5, 2022 01:01 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	19,129	$14.24	$272,333.83	Disclosure SEC source: 0001104659-22-086343 · tm2222660-1_4seq1.xml · nonDerivative · entry 2 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281,952 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
August 02, 2022 Filed Aug 5, 2022 01:01 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	4,792	$14.10	$67,554.26	Disclosure SEC source: 0001104659-22-086343 · tm2222660-1_4seq1.xml · nonDerivative · entry 1 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,081 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
July 28, 2022 Filed Aug 1, 2022 20:35 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	3,253,796	$4.61	$14,999,999.56	Disclosure SEC source: 0000899243-22-027171 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By ElevateBio LLC Disclosed balance after: 16,674,766 F1 · kind: On July 28, 2022, F2 MG Limited ("F2 MG"), F2-TPO Investments LLC ("F2-TPO"), F2 MC LLC ("F2 MC"), F2 Capital I 2020 LLC ("F2 2020"), F2 Bioscience AV 2022 LLC ("F2 2022") and ElevateBio LLC ("ElevateBio") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F7 · ownership.nature: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
July 28, 2022 Filed Aug 1, 2022 20:35 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	867,678	$4.61	$3,999,995.58	Disclosure SEC source: 0000899243-22-027171 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 Bioscience AV 2022 LLC Disclosed balance after: 867,678 F1 · kind: On July 28, 2022, F2 MG Limited ("F2 MG"), F2-TPO Investments LLC ("F2-TPO"), F2 MC LLC ("F2 MC"), F2 Capital I 2020 LLC ("F2 2020"), F2 Bioscience AV 2022 LLC ("F2 2022") and ElevateBio LLC ("ElevateBio") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F6 · ownership.nature: Shares held by F2 2022. Globeways Holdings II Limited is the appointed manager of F2 2022 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2022. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
July 28, 2022 Filed Aug 1, 2022 20:35 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	1,393,874	$4.61	$6,425,759.14	Disclosure SEC source: 0000899243-22-027171 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 Capital I 2020 LLC Disclosed balance after: 4,193,874 F1 · kind: On July 28, 2022, F2 MG Limited ("F2 MG"), F2-TPO Investments LLC ("F2-TPO"), F2 MC LLC ("F2 MC"), F2 Capital I 2020 LLC ("F2 2020"), F2 Bioscience AV 2022 LLC ("F2 2022") and ElevateBio LLC ("ElevateBio") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F5 · ownership.nature: Shares held by F2 2020. Globeways Holdings II Limited is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
July 28, 2022 Filed Aug 1, 2022 20:35 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	1,626,898	$4.61	$7,499,999.78	Disclosure SEC source: 0000899243-22-027171 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MC, LLC Disclosed balance after: 2,038,583 F1 · kind: On July 28, 2022, F2 MG Limited ("F2 MG"), F2-TPO Investments LLC ("F2-TPO"), F2 MC LLC ("F2 MC"), F2 Capital I 2020 LLC ("F2 2020"), F2 Bioscience AV 2022 LLC ("F2 2022") and ElevateBio LLC ("ElevateBio") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F4 · ownership.nature: Shares held by F2 MC. Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
July 28, 2022 Filed Aug 1, 2022 20:35 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	325,379	$4.61	$1,499,997.19	Disclosure SEC source: 0000899243-22-027171 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 668,072 F1 · kind: On July 28, 2022, F2 MG Limited ("F2 MG"), F2-TPO Investments LLC ("F2-TPO"), F2 MC LLC ("F2 MC"), F2 Capital I 2020 LLC ("F2 2020"), F2 Bioscience AV 2022 LLC ("F2 2022") and ElevateBio LLC ("ElevateBio") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
July 28, 2022 Filed Aug 1, 2022 20:35 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantCommon Stock	684,622	$4.61	$3,156,107.42	Disclosure SEC source: 0000899243-22-027171 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 2,059,884 F1 · kind: On July 28, 2022, F2 MG Limited ("F2 MG"), F2-TPO Investments LLC ("F2-TPO"), F2 MC LLC ("F2 MC"), F2 Capital I 2020 LLC ("F2 2020"), F2 Bioscience AV 2022 LLC ("F2 2022") and ElevateBio LLC ("ElevateBio") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 24, 2022 Filed Jun 29, 2022 01:24 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	Exercise / conversionStock Option (Right to Buy) · Derivative	35,529	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · derivative · entry 13 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,529 shares Expires 2022-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
June 24, 2022 Filed Jun 29, 2022 01:24 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	Exercise / conversionStock Option (Right to Buy) · Derivative	104,845	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · derivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,845 shares Expires 2022-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document
June 24, 2022 Filed Jun 29, 2022 01:24 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	Tax withholdingCommon Stock	45,078	$13.39	$603,594.42	Disclosure SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,803 F1 · kind: Represents a net exercise of outstanding stock options. These shares were resold to the Issuer as payment of the exercise price, based on the closing price of the Issuer's common stock on June 24, 2022 of $13.39 per share. Read SEC document
June 24, 2022 Filed Jun 29, 2022 01:24 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	Exercise / conversionCommon Stock	35,529	$4.30	$152,774.70	Disclosure SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2022 Filed Jun 29, 2022 01:24 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	Exercise / conversionCommon Stock	104,845	$4.30	$450,833.50	Disclosure SEC source: 0001104659-22-075392 · tm2219571-1_4seq1.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 23, 2022 Filed Jun 23, 2022 22:47 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	29,631	$13.00	$385,309.67	Disclosure SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 3 F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,392 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 22, 2022 Filed Jun 23, 2022 22:47 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	49,953	$12.70	$634,577.94	Disclosure SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 2 F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,023 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
June 21, 2022 Filed Jun 23, 2022 22:47 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	22,319	$12.77	$284,928.82	Disclosure SEC source: 0001104659-22-073980 · tm2219298-1_4seq1.xml · nonDerivative · entry 1 F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,976 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways Holdings Limited ("Globeways") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 17, 2022 Filed May 19, 2022 20:28 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantStock Option (Right to Buy) · Derivative	27,500	$0.00 Strike: $4.60	$0.00	Disclosure SEC source: 0000899243-22-018836 · doc4.xml · derivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
May 16, 2022 Filed May 17, 2022 00:54 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	35,158	$11.23	$394,827.86	Disclosure SEC source: 0001104659-22-061591 · tm2215669-1_4seq1.xml · nonDerivative · entry 4 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,873 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 13, 2022 Filed May 17, 2022 00:54 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	34,189	$10.48	$358,334.91	Disclosure SEC source: 0001104659-22-061591 · tm2215669-1_4seq1.xml · nonDerivative · entry 3 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,341,031 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.40 to $10.65, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 13, 2022 Filed May 17, 2022 00:54 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	85,319	$9.96	$850,041.73	Disclosure SEC source: 0001104659-22-061591 · tm2215669-1_4seq1.xml · nonDerivative · entry 2 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375,220 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $10.395, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 12, 2022 Filed May 17, 2022 00:54 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	264,072	$9.25	$2,442,586.78	Disclosure SEC source: 0001104659-22-061591 · tm2215669-1_4seq1.xml · nonDerivative · entry 1 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,460,539 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.58, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.direct: These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 11, 2022 Filed Jan 13, 2022 22:22 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	OtherCommon Stock	1,187,734	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-001926 · doc4.xml · nonDerivative · entry 1 F2 Vision SCS · CIK 0001838409 · 10% owner Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,724,611 F1 · kind: On January 11, 2022, F2 Vision SCS ("F2 Vision") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the "Shares") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On January 11, 2022, F2 Vision SCS ("F2 Vision") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the "Shares") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These securities are owned directly by F2 Vision. F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 10, 2021 Filed Nov 15, 2021 22:17 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	120	$24.77	$2,971.80	Disclosure SEC source: 0000899243-21-044619 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 342,693 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 10, 2021 Filed Nov 15, 2021 22:17 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	680	$24.77	$16,840.20	Disclosure SEC source: 0000899243-21-044619 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,375,262 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 09, 2021 Filed Nov 9, 2021 23:43 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	572	$24.79	$14,178.85	Disclosure SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 342,813 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.825, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 09, 2021 Filed Nov 9, 2021 23:43 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	3,243	$24.79	$80,388.13	Disclosure SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,375,942 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.825, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 05, 2021 Filed Nov 9, 2021 23:43 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	1,257	$24.80	$31,179.51	Disclosure SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 343,385 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
November 05, 2021 Filed Nov 9, 2021 23:43 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	7,124	$24.80	$176,708.68	Disclosure SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,379,185 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 27, 2021 Filed Oct 29, 2021 21:02 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	330	$24.78	$8,176.58	Disclosure SEC source: 0000899243-21-042033 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 344,642 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.805, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 27, 2021 Filed Oct 29, 2021 21:02 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	1,870	$24.78	$46,333.93	Disclosure SEC source: 0000899243-21-042033 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,386,309 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.805, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 25, 2021 Filed Oct 25, 2021 22:24 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	1,165	$24.82	$28,913.32	Disclosure SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 344,972 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 25, 2021 Filed Oct 25, 2021 22:24 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	6,604	$24.82	$163,900.05	Disclosure SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,388,179 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 22, 2021 Filed Oct 25, 2021 22:24 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	859	$24.77	$21,277.17	Disclosure SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 346,137 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 22, 2021 Filed Oct 25, 2021 22:24 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	4,864	$24.77	$120,479.82	Disclosure SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,394,783 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 21, 2021 Filed Oct 25, 2021 22:24 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	15	$24.75	$371.25	Disclosure SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2-TPO Investments, LLC Disclosed balance after: 346,996 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 21, 2021 Filed Oct 25, 2021 22:24 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	SaleCommon Stock	85	$24.75	$2,103.75	Disclosure SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By F2 MG Limited Disclosed balance after: 1,399,647 F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021. F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
September 16, 2021 Filed Mar 25, 2022 23:32 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $28.80	$0.00	Disclosure SEC source: 0000899243-22-012373 · doc4.xml · derivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document
May 25, 2021 Filed May 27, 2021 20:45 UTC	Kalaris Therapeutics, Inc. ALVR · Entity 6805	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $21.51	$0.00	Disclosure SEC source: 0000899243-21-020859 · doc4.xml · derivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-24 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries C Convertible Preferred Stock · Derivative	1,511,966	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 21 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 214,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F8 · ownership.nature: These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries C Convertible Preferred Stock · Derivative	503,988	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 20 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 71,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F7 · ownership.nature: These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries C Convertible Preferred Stock · Derivative	1,007,977	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 19 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 143,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries C Convertible Preferred Stock · Derivative	503,988	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 18 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 71,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries B Convertible Preferred Stock · Derivative	1,282,051	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 17 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 182,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F6 · ownership.nature: These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries B Convertible Preferred Stock · Derivative	3,205,128	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 16 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 455,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F5 · ownership.nature: These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
January 12, 2021 Filed Jan 14, 2021 22:30 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	ConversionSeries A Convertible Preferred Stock · Derivative	4,500,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-002048 · doc4.xml · derivative · entry 15 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner F2 Vision SCS · CIK 0001838409 · 10% owner F2 Bioscience I 2017 Ltd · CIK 0001838573 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 Bio TD, LLC · CIK 0001838330 · 10% owner F2 MC, LLC · CIK 0001838426 · 10% owner F2 GC, LLC · CIK 0001840637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 639,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date. F4 · ownership.nature: These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.